| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.016 | 0.9 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.017 | 0.9 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |